TSG6 polypeptide fragment for dry eye
DE602020047923T2Active Publication Date: 2025-03-19UNIV OF MANCHESTER
0 Cites 0 Cited by
Patent Information
- Application Number
- DE602020047923
- Authority / Receiving Office
- DE · DE
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-07-25
- Filing Date
- 2020-06-23
- Publication Date
- 2025-03-19
- Estimated Expiration
- 2040-06-23
AI Technical Summary
Technical Problem
Current treatments for dry eye disease, such as topical TSG-6, are limited by difficulties in large-scale production and stability issues of the recombinant protein.
Method used
The use of a LINK_TSG6 polypeptide, which is a fragment of TSG-6, for the treatment or prevention of dry eye disease, offering improved potency and stability compared to full-length TSG-6.
Benefits of technology
LINK_TSG6 effectively reduces corneal epithelial defects, increases tear production, suppresses inflammation, and preserves conjunctival goblet cells in a dose-dependent manner, outperforming full-length TSG-6 in these aspects.
✦ Generated by Eureka AI based on patent content.
Need to check novelty before this filing date? Find Prior Art
No text content released.